March 2022. Volume 18. Number 1

ARN vaccine BNY162b2 against COVID-19 appears safe and effective in children older than 4 years

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022;386:35-46.
Reviewers: Fraile Astorga G1, Esparza Olcina MJ2.
1Pediatra. CAP Can Rull. Sabadell. Barcelona. España.
2Pediatra de Atención Primaria. Madrid. España.
Correspondence: Garazi Fraile Astorga. Email: garazifraile@hotmail.com
Reception date: 13/01/2022
Acceptance date: 27/01/2022
Publication date: 09/02/2022

Abstract

Authors’ conclusions: a COVID-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age. 

Reviewers’ commentary: vaccine BNT162b2 produces a robust immune response similar to young adults. It is a safe vaccine with transient mild to moderate reactogenicity. The vaccine efficaciousness is high against COVID-19, but low incidence of serious illness in this age group, the short follow-up of the vaccinated group and the mutation capacity of the virus makes it necessary to continue investigating to measure the impact on hospitalization and protection against serious COVID-19.

Key words: children; COVID-19; vaccine

How to cite this article

Fraile Astorga G, Esparza Olcina MJ. La vacuna de ARN BNT162b2 frente a la COVID-19 parece segura y eficaz en niños mayores de 4 años. Evid Pediatr. 2022;18:5.

AVC | Critically appraised articles

Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022;386:35-46.
Reviewers: Fraile Astorga G1, Esparza Olcina MJ2.
1Pediatra. CAP Can Rull. Sabadell. Barcelona. España.
2Pediatra de Atención Primaria. Madrid. España.
Correspondence: Garazi Fraile Astorga. Email: garazifraile@hotmail.com
Key words: children; COVID-19; vaccine
Reception date: 13/01/2022
Acceptance date: 27/01/2022
Publication date: 09/02/2022

How to cite this article

Fraile Astorga G, Esparza Olcina MJ. La vacuna de ARN BNT162b2 frente a la COVID-19 parece segura y eficaz en niños mayores de 4 años. Evid Pediatr. 2022;18:5.

09/02/2022

Linked Comment